Hologic vs. Minerva: Surgical Device Patent Case Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Hologic, Inc. v. Minerva Surgical, Inc. |
| Case Number | 1:20-cv-00925-JFB-SRF (D. Del.) |
| Court | United States District Court for the District of Delaware |
| Duration | July 9, 2020 – Dismissed Voluntary Dismissal |
| Outcome | Case Dismissed |
| Patents at Issue | Specific patent numbers were not disclosed in the available case data. |
| Accused Products | Minerva Surgical’s endometrial ablation system |
Case Overview
The Parties
⚖️ Plaintiff
Leading global medical technology company with a substantial portfolio in women’s health diagnostics and surgical solutions, including endometrial ablation platforms.
🛡️ Defendant
Medical device company focused on developing innovative solutions for abnormal uterine bleeding, a direct competitor to Hologic in the endometrial ablation market.
The Patent(s) at Issue
The dispute centered on patent rights within the endometrial ablation technology space. Endometrial ablation devices are used to treat abnormal uterine bleeding by destroying the uterine lining, and the underlying IP covers complex electrosurgical and fluid management systems that differentiate competing platforms.
(Specific patent numbers were not disclosed in the available case data. Practitioners should consult PACER or the USPTO patent database for the complete patent schedule filed in this matter.)
Developing a surgical medical device?
Check if your device design or technology might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was terminated by voluntary dismissal, meaning no court-rendered verdict on the merits of infringement, validity, or damages was issued. This outcome forecloses a definitive public ruling but does not eliminate the strategic significance of how and why the parties arrived at this resolution.
No damages award or injunctive relief determination was entered by the court as part of the public record in this matter.
Key Legal Issues
Voluntary dismissal under Federal Rule of Civil Procedure 41 can be initiated by the plaintiff (Rule 41(a)) or by court order (Rule 41(b)). In patent litigation, plaintiff-initiated voluntary dismissals frequently coincide with confidential settlement agreements, claim reassessment, parallel PTAB proceedings, or business-driven strategic pivots.
Given the history between Hologic and Minerva — which includes the landmark Minerva Surgical, Inc. v. Hologic, Inc. Supreme Court decision in 2021 addressing assignor estoppel — this case exists within a richly complex litigation ecosystem. Practitioners analyzing this dismissal should consider it in the full context of the parties’ broader patent dispute history.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in medical device development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation in medical devices.
- View all related patents in the endometrial ablation space
- See which companies are most active in medical device IP
- Understand claim construction patterns in surgical tech
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own medical technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Endometrial ablation devices and similar gynecological surgical tech
200+ Related Patents
In medical device surgical space
Design-Around Options
Available with careful analysis
✅ Key Takeaways
Voluntary dismissal in patent cases does not resolve the underlying IP dispute — evaluate whether it is with or without prejudice.
Search related case law →Delaware remains a strategically favorable venue for complex medical device patent litigation.
Explore court analytics →Frequently Asked Questions
The case was terminated by voluntary dismissal, meaning no court verdict on infringement or validity was rendered publicly.
While distinct proceedings, both cases are part of an extensive IP enforcement conflict between Hologic and Minerva Surgical over endometrial ablation technology, with the Supreme Court case addressing assignor estoppel doctrine.
Companies in the surgical device space should conduct thorough FTO analyses, monitor multi-forum patent disputes between market leaders, and build IP clearance into product development pipelines.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER (Public Access to Court Electronic Records)
- U.S. Patent and Trademark Office (USPTO) Patent Database
- Minerva Surgical, Inc. v. Hologic, Inc., 141 S. Ct. 2298 (2021)
- Federal Rule of Civil Procedure 41
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.